Onco-Innovations Engages Investment Bank to Pursue Nasdaq Cross-listing and Potential Concurrent Equity Offering

Executive Summary

• Onco‑Innovations Limited has engaged a U.S. investment bank to act as its capital markets advisor for a potential Nasdaq cross‑listing and concurrent equity financing.
• The advisory mandate will cover listing requirements, regulatory considerations, and capitalization strategies needed to pursue the contemplated transactions.
• No assurance is given that either the cross‑listing or the financing will be completed; both remain subject to regulatory and exchange approvals.

Key Details

• Engagement of a U.S. investment bank as capital markets advisor for evaluating a Nasdaq cross‑listing and possible equity raise.
• The advisory scope includes analysis of listing requirements, regulatory considerations, and capitalization strategies.
• Structure and terms of any contemplated financing have not yet been finalized.
• Company explicitly states that completion of the cross‑listing or financing is uncertain and contingent on meeting applicable requirements.

Notable Quotes

• “The engagement forms part of the Company's ongoing evaluation of options intended to support long‑term corporate development.” – Thomas O'Shaughnessy, Chief Executive Officer

Materiality Assessment: Non‑Material – Positive (the announcement signals strategic intent but does not yet constitute a definitive financing or listing transaction).